New drug combo tested against standard treatment for blood cancer
NCT ID NCT07171827
Summary
This study compared two different chemotherapy combinations for people newly diagnosed with advanced Hodgkin lymphoma. Researchers tested whether replacing one drug (bleomycin) with a targeted medication (brentuximab vedotin) would work as well or better while potentially causing fewer side effects. The trial involved 60 adults with stage III or IV disease who hadn't received prior treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-CD30 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Helwan University
Helwan, 11795, Egypt
Conditions
Explore the condition pages connected to this study.